≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Acanthosis nigricans

DOID EFO Endpoint Browser PheWeb

L12_ACANTHNIGRICANS

acanthosis nigricans: a brown to black, poorly defined, velvety hyperpigmentation of the skin. It is usually found in body folds, such as the posterior and lateral folds of the neck, the armpits, groin, navel, forehead, and other areas.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — L83
  • Hospital discharge: ICD-9 — 7012A
  • Hospital discharge: ICD-8 — 7011
  • Cause of death: ICD-10 — L83
  • Cause of death: ICD-9 — 7012A
  • Cause of death: ICD-8 — 7011

2 out of 7 registries used, show all original rules.

129

4. Check minimum number of events

None

129

5. Include endpoints

None

129

6. Filter based on genotype QC (FinnGen only)

120

Control definitions (FinnGen only)

Control exclude
L12_OTHERSKINSUBCUTIS

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
L80-L99
Name in latin
Acanthosis nigricans

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1289 650 620
Only index persons 1001 528 473
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.02
Only index persons 0.02 0.02 0.02
Median age at first event (years)
Whole population 35.84 38.52 32.41
Only index persons 27.01 31.54 21.95

-FinnGen-

Key figures

All Female Male
Number of individuals 120 71 49
Unadjusted period prevalence (%) 0.02 0.03 0.02
Median age at first event (years) 28.77 32.96 22.71

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
129
Matched controls
1290
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L83
ICD-10 Finland
Acanthosis nigricans
+∞
90.6
76
*
70119
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Keratosis, hyperkeratosis alia sive NUD
+∞
32.7
30
*
SPAT1148
SPAT
Treatment of chronic ulcer or burn
5.8
13.3
28
59
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.8
13.3
23
40
70115
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Ichthyosis
+∞
12.7
12
*
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
4.5
8.7
24
63
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
4.3
8.5
25
69
D01AC02
ATC
miconazole; topical
7.8
8.4
19
28
70110
ICD-8 Finland
Other hypertrophic and atrophic conditions of the skin, Keratoderma acquisitum (Kämmen, jalkapohja) (palmare, plantare)
+∞
8.4
8
*
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
23.8
8.2
11
5
J01FF01
ATC
clindamycin; systemic
3.0
7.9
49
219
J01MA12
ATC
levofloxacin; systemic
3.4
7.8
33
117
R60.0
ICD-10 Finland
Localized oedema
3.9
7.6
25
75
L89
ICD-10 Finland
Decubitus ulcer and pressure area
84.8
7.5
8
*
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.1
7.3
39
159
H02AB06
ATC
prednisolone; systemic
2.7
7.0
69
389
E66.9
ICD-10 Finland
Obesity, unspecified
7.9
6.9
15
21
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
6.5
38
163
E000001, ,
ATC
2.8
6.1
38
167
E66.00
ICD-10 Finland
Metabolic syndrome
4.4
6.1
16
40

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.5e+00
2.3e+00
—
1.0e+50
2.9e+00
3.3e+00
1.5e+00
cases:18.60%
controls:4.68%
cases:17.44%
controls:1.99%
—
—
cases:67.44%
controls:0.00%
cases:11.63%
controls:0.70%
cases:32.56%
controls:1.66%
cases:25.00%
controls:7.22%
16
40
70
815
15
17
71
838
—
58
0
28
855
10
6
76
849
28
14
58
829
20
56
60
720
Supplier / Service Provider
OMOP5117446 [33004]
-1.0e+00
—
-1.0e+50
—
—
2.7e+00
2.8e+00
cases:12.79%
controls:28.54%
—
—
cases:0.00%
controls:1.05%
—
—
—
—
cases:8.14%
controls:0.59%
cases:10.00%
controls:0.64%
11
244
75
611
—
0
9
86
846
—
—
7
5
79
838
8
5
72
771
Sleep apnoea
G47.3 [45562094]
1.7e+00
2.4e+00
—
—
—
—
2.1e+00
cases:8.14%
controls:1.64%
cases:9.30%
controls:0.94%
—
—
—
—
—
—
—
—
cases:12.50%
controls:1.68%
7
14
79
841
8
8
78
847
—
—
—
—
10
13
70
763
combinations of corticosteroids
D07AB30 [21602118]
1.1e+00
1.9e+00
—
—
—
1.4e+00
1.1e+00
cases:19.77%
controls:7.72%
cases:12.79%
controls:2.11%
—
—
—
—
—
—
cases:9.30%
controls:2.49%
cases:26.25%
controls:10.31%
17
66
69
789
11
18
75
837
—
—
—
8
21
78
822
21
80
59
696
combinations of corticosteroids
D07XB30 [21602188]
1.1e+00
1.9e+00
—
—
—
1.4e+00
1.1e+00
cases:19.77%
controls:7.72%
cases:12.79%
controls:2.11%
—
—
—
—
—
—
cases:9.30%
controls:2.49%
cases:26.25%
controls:10.31%
17
66
69
789
11
18
75
837
—
—
—
8
21
78
822
21
80
59
696
Physiotherapy
R4110 [2001310233]
—
—
—
—
—
2.2e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:6.98%
controls:0.83%
cases:12.50%
controls:2.19%
—
—
—
—
—
6
7
80
836
10
17
70
759
Gastroenterology
10 [38004455]
1.2e+00
—
—
—
—
2.2e+00
1.5e+00
cases:9.30%
controls:2.92%
—
—
—
—
—
—
—
—
cases:9.30%
controls:1.07%
cases:16.25%
controls:3.99%
8
25
78
830
—
—
—
—
8
9
78
834
13
31
67
745
Outpatient Visit
OP [9202]
6.5e-01
1.3e+00
5.8e-01
—
1.2e+00
1.2e+00
6.9e-01
cases:73.26%
controls:58.95%
cases:69.77%
controls:38.95%
cases:16.28%
controls:9.82%
—
—
cases:24.42%
controls:8.54%
cases:67.44%
controls:39.50%
cases:81.25%
controls:68.43%
63
504
23
351
60
333
26
522
14
84
72
771
—
21
73
65
782
58
333
28
510
65
531
15
245
Case Management Agency
251B00000X [38004193]
1.6e-01
1.6e-01
7.0e-01
3.6e+00
4.5e-01
1.8e-01
4.9e-01
cases:48.84%
controls:44.91%
cases:45.35%
controls:41.40%
cases:25.58%
controls:14.62%
cases:18.60%
controls:0.58%
cases:23.26%
controls:16.14%
cases:46.51%
controls:42.11%
cases:70.00%
controls:58.89%
42
384
44
471
39
354
47
501
22
125
64
730
16
5
70
850
20
138
66
717
40
355
46
488
56
457
24
319
Internal Medicine
11 [38004456]
7.5e-01
1.1e+00
—
1.0e+50
—
1.1e+00
1.1e+00
cases:27.91%
controls:15.44%
cases:19.77%
controls:7.37%
—
—
cases:6.98%
controls:0.00%
—
—
cases:18.60%
controls:7.35%
cases:38.75%
controls:17.78%
24
132
62
723
17
63
69
792
—
6
0
80
855
—
16
62
70
781
31
138
49
638
cefalexin; oral
J01DB01 [21602870]
9.1e-01
1.2e+00
1.5e+00
—
—
1.1e+00
7.6e-01
cases:46.51%
controls:25.85%
cases:20.93%
controls:7.25%
cases:5.81%
controls:1.40%
—
—
—
—
cases:22.09%
controls:8.54%
cases:46.25%
controls:28.61%
40
221
46
634
18
62
68
793
5
12
81
843
—
—
19
72
67
771
37
222
43
554
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.2e+00
8.0e-01
—
—
—
1.9e+00
1.3e+00
cases:12.79%
controls:4.21%
cases:5.81%
controls:2.69%
—
—
—
—
—
—
cases:9.30%
controls:1.54%
cases:15.00%
controls:4.38%
11
36
75
819
5
23
81
832
—
—
—
8
13
78
830
12
34
68
742
Pharmacy visit
OMOP4822462 [581458]
3.4e-01
7.4e-01
1.0e+00
2.1e+00
6.6e-01
8.1e-01
3.7e-01
cases:87.21%
controls:82.92%
cases:83.72%
controls:71.11%
cases:56.98%
controls:32.63%
cases:13.95%
controls:1.87%
cases:48.84%
controls:32.98%
cases:86.05%
controls:73.31%
cases:90.00%
controls:86.08%
75
709
11
146
72
608
14
247
49
279
37
576
12
16
74
839
42
282
44
573
74
618
12
225
72
668
8
108
Inpatient Hospital
21 [8717]
3.6e-01
7.2e-01
2.2e+00
1.0e+50
—
5.1e-01
9.0e-01
cases:39.53%
controls:31.23%
cases:17.44%
controls:9.36%
cases:6.98%
controls:0.82%
cases:10.47%
controls:0.00%
—
—
cases:13.95%
controls:8.90%
cases:43.75%
controls:23.97%
34
267
52
588
15
80
71
775
6
7
80
848
9
0
77
855
—
12
75
74
768
35
186
45
590
General Surgery
2 [38004447]
7.1e-01
1.1e+00
2.5e+00
1.0e+50
—
1.2e+00
5.5e-01
cases:23.26%
controls:12.98%
cases:12.79%
controls:4.68%
cases:6.98%
controls:0.58%
cases:13.95%
controls:0.00%
—
—
cases:12.79%
controls:4.03%
cases:22.50%
controls:14.30%
20
111
66
744
11
40
75
815
6
5
80
850
12
0
74
855
—
11
34
75
809
18
111
62
665
Scheduled procedure
ZXD10 [2001311387]
1.1e+00
1.7e+00
—
—
—
2.5e+00
8.8e-01
cases:12.79%
controls:4.44%
cases:6.98%
controls:1.40%
—
—
—
—
—
—
cases:8.14%
controls:0.71%
cases:10.00%
controls:4.38%
11
38
75
817
6
12
80
843
—
—
—
7
6
79
837
8
34
72
742
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
3.6e-01
4.4e-01
—
—
2.4e+00
5.4e-01
3.5e-01
cases:19.77%
controls:14.62%
cases:10.47%
controls:7.02%
—
—
—
—
cases:6.98%
controls:0.70%
cases:11.63%
controls:7.12%
cases:26.25%
controls:19.97%
17
125
69
730
9
60
77
795
—
—
6
6
80
849
10
60
76
783
21
155
59
621
lansoprazole; oral
A02BC03 [21600098]
1.5e+00
2.4e+00
—
—
—
—
1.2e+00
cases:8.14%
controls:1.87%
cases:6.98%
controls:0.70%
—
—
—
—
—
—
—
—
cases:10.00%
controls:3.35%
7
16
79
839
6
6
80
849
—
—
—
—
8
26
72
750
dexamethasone and antiinfectives
S02CA06 [21605178]
2.3e+00
—
—
—
—
—
—
cases:5.81%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
81
850
—
—
—
—
—
—
Vascular Surgery
77 [38004496]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:1.16%
—
—
—
—
—
—
8
9
72
767
One hour or less
ZXE00 [2001311394]
1.0e+00
—
—
—
—
2.2e+00
1.2e+00
cases:12.79%
controls:5.03%
—
—
—
—
—
—
—
—
cases:8.14%
controls:0.95%
cases:12.50%
controls:4.25%
11
43
75
812
—
—
—
—
7
8
79
835
10
33
70
743
other preparations, combinations; ointment
C05AX03 [21601631]
1.1e+00
—
—
—
—
—
2.1e+00
cases:6.98%
controls:2.34%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:1.29%
6
20
80
835
—
—
—
—
—
8
10
72
766
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
2.1e+00
—
—
—
—
—
—
cases:8.14%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
79
846
—
—
—
—
—
—
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:1.16%
—
—
—
—
—
—
7
9
73
767
antibiotics in combination with corticosteroids
D01AA20 [21601918]
2.1e+00
—
—
—
—
—
—
cases:6.98%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
80
847
—
—
—
—
—
—
tranexamic acid; oral, parenteral
B02AA02 [21601036]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:1.03%
—
—
—
—
—
—
6
8
74
768
Obesity due to excess calories
E66.01 [2000501501]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:1.29%
—
—
—
—
—
—
7
10
73
766
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
—
—
—
—
—
2.0e+00
4.9e-01
—
—
—
—
—
—
—
—
—
—
cases:9.30%
controls:1.42%
cases:8.75%
controls:5.54%
—
—
—
—
—
8
12
78
831
7
43
73
733
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
—
—
—
—
—
2.0e+00
4.9e-01
—
—
—
—
—
—
—
—
—
—
cases:9.30%
controls:1.42%
cases:8.75%
controls:5.54%
—
—
—
—
—
8
12
78
831
7
43
73
733
Other specified special examinations
Z01.8 [45581003]
1.8e+00
—
—
—
—
-1.0e+50
1.4e+00
cases:8.14%
controls:1.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
cases:7.50%
controls:1.93%
7
12
79
843
—
—
—
—
0
10
86
833
6
15
74
761
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
3.8e-01
-1.0e+50
—
—
—
1.8e+00
1.1e+00
cases:9.30%
controls:6.55%
cases:0.00%
controls:2.22%
—
—
—
—
—
—
cases:9.30%
controls:1.66%
cases:15.00%
controls:5.28%
8
56
78
799
0
19
86
836
—
—
—
8
14
78
829
12
41
68
735
Coloscopy
UJF32 [2001305029]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.75%
controls:2.58%
—
—
—
—
—
—
11
20
69
756
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.25%
controls:2.06%
—
—
—
—
—
—
9
16
71
760
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
6.6e-01
-1.0e+50
—
—
—
—
1.8e+00
cases:6.98%
controls:3.74%
cases:0.00%
controls:1.75%
—
—
—
—
—
—
—
—
cases:15.00%
controls:2.96%
6
32
80
823
0
15
86
840
—
—
—
—
12
23
68
753
Endocrinology
46 [38004485]
1.2e+00
1.4e+00
—
—
—
1.7e+00
9.3e-01
cases:8.14%
controls:2.57%
cases:5.81%
controls:1.52%
—
—
—
—
—
—
cases:10.47%
controls:2.02%
cases:11.25%
controls:4.77%
7
22
79
833
5
13
81
842
—
—
—
9
17
77
826
9
37
71
739
Rheumatology
66 [38004491]
1.7e+00
—
—
—
—
—
1.0e+00
cases:9.30%
controls:1.87%
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:2.84%
8
16
78
839
—
—
—
—
—
6
22
74
754
calcium (different salts in combination); oral
A12AA20 [21600872]
6.9e-01
1.4e+00
—
—
—
1.7e+00
1.1e+00
cases:6.98%
controls:3.63%
cases:9.30%
controls:2.57%
—
—
—
—
—
—
cases:10.47%
controls:2.14%
cases:15.00%
controls:5.54%
6
31
80
824
8
22
78
833
—
—
—
9
18
77
825
12
43
68
733
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
9.5e-01
2.0e+00
—
—
—
1.7e+00
1.6e+00
cases:5.81%
controls:2.34%
cases:5.81%
controls:0.82%
—
—
—
—
—
—
cases:5.81%
controls:1.07%
cases:13.75%
controls:3.09%
5
20
81
835
5
7
81
848
—
—
—
5
9
81
834
11
24
69
752
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.50%
controls:2.84%
—
—
—
—
—
—
10
22
70
754
salbutamol; inhalant
R03AC02 [21603256]
8.3e-01
4.2e-01
-1.0e+50
—
-1.0e+50
1.5e+00
9.2e-01
cases:19.77%
controls:9.71%
cases:9.30%
controls:6.32%
cases:0.00%
controls:0.82%
—
—
cases:0.00%
controls:0.70%
cases:15.12%
controls:3.68%
cases:23.75%
controls:11.08%
17
83
69
772
8
54
78
801
0
7
86
848
—
0
6
86
849
13
31
73
812
19
86
61
690
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
1.5e+00
-1.0e+50
—
—
—
—
—
cases:10.47%
controls:2.46%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
9
21
77
834
0
8
86
847
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
5.1e-01
—
—
—
—
—
1.4e+00
cases:6.98%
controls:4.33%
—
—
—
—
—
—
—
—
—
—
cases:18.75%
controls:5.28%
6
37
80
818
—
—
—
—
—
15
41
65
735
Infiltration anesthesia
WX110 [2001310767]
5.5e-01
2.1e-01
—
—
—
1.4e+00
3.7e-01
cases:22.09%
controls:14.04%
cases:6.98%
controls:5.73%
—
—
—
—
—
—
cases:17.44%
controls:4.98%
cases:23.75%
controls:17.65%
19
120
67
735
6
49
80
806
—
—
—
15
42
71
801
19
137
61
639
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.0e-01
—
—
—
—
1.3e+00
1.3e+00
cases:8.14%
controls:4.21%
—
—
—
—
—
—
—
—
cases:6.98%
controls:2.02%
cases:16.25%
controls:4.90%
7
36
79
819
—
—
—
—
6
17
80
826
13
38
67
738
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
1.3e+00
—
—
—
—
—
1.5e-01
cases:15.12%
controls:4.68%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:7.60%
13
40
73
815
—
—
—
—
—
7
59
73
717
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
3.7e-01
1.0e+00
—
—
—
—
1.2e+00
cases:5.81%
controls:4.09%
cases:6.98%
controls:2.57%
—
—
—
—
—
—
—
—
cases:17.50%
controls:6.06%
5
35
81
820
6
22
80
833
—
—
—
—
14
47
66
729
Pulmonary Disease
29 [38004472]
1.0e+00
1.1e+00
—
—
—
1.1e+00
1.2e+00
cases:13.95%
controls:5.38%
cases:6.98%
controls:2.46%
—
—
—
—
—
—
cases:6.98%
controls:2.37%
cases:16.25%
controls:5.67%
12
46
74
809
6
21
80
834
—
—
—
6
20
80
823
13
44
67
732
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
7.8e-01
1.1e+00
—
—
—
7.8e-01
1.1e+00
cases:13.95%
controls:6.90%
cases:9.30%
controls:3.27%
—
—
—
—
—
—
cases:6.98%
controls:3.32%
cases:18.75%
controls:7.09%
12
59
74
796
8
28
78
827
—
—
—
6
28
80
815
15
55
65
721
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
9.5e-01
1.1e+00
—
—
—
7.8e-01
1.1e+00
cases:15.12%
controls:6.43%
cases:9.30%
controls:3.27%
—
—
—
—
—
—
cases:6.98%
controls:3.32%
cases:18.75%
controls:7.22%
13
55
73
800
8
28
78
827
—
—
—
6
28
80
815
15
56
65
720
Outpatient Hospital
22 [8756]
1.0e+00
6.3e-01
—
1.0e+50
—
1.2e+00
8.6e-01
cases:39.53%
controls:19.18%
cases:10.47%
controls:5.85%
—
—
cases:6.98%
controls:0.00%
—
—
cases:13.95%
controls:4.86%
cases:32.50%
controls:16.88%
34
164
52
691
9
50
77
805
—
6
0
80
855
—
12
41
74
802
26
131
54
645
Pregnancy
W78 [2002001269]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.05%
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
0
9
86
846
0
5
86
850
—
0
5
86
850
—
—
salmeterol; inhalant
R03AC12 [21603266]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
Screening procedure
SPAT1324 [2001700425]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
0
9
86
846
—
—
—
0
6
86
837
—
Pure hypercholesterolaemia
E78.0 [45542771]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
0
5
86
850
0
6
86
849
—
—
—
0
7
86
836
—
Bacteria identified in Isolate by Culture
43409-2 [3042936]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.77%
—
—
—
—
—
—
5
6
75
770
Basophils/Leukocytes in Blood
30180-4 [3022096]
9.0e-01
1.1e+00
—
—
—
8.2e-01
1.0e+00
cases:13.95%
controls:6.20%
cases:9.30%
controls:3.27%
—
—
—
—
—
—
cases:6.98%
controls:3.20%
cases:17.50%
controls:6.96%
12
53
74
802
8
28
78
827
—
—
—
6
27
80
816
14
54
66
722
hydroxyzine; oral, parenteral
N05BB01 [21604590]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.68%
—
—
—
—
—
—
5
13
75
763
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
86
844
—
—
—
—
—
—
phenylephrine, combinations
R01BA53 [21603214]
1.5e+00
—
—
—
—
—
—
cases:8.14%
controls:1.99%
—
—
—
—
—
—
—
—
—
—
—
—
7
17
79
838
—
—
—
—
—
—
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
4.4e-01
-1.0e+50
—
—
—
—
6.4e-01
cases:8.14%
controls:5.38%
cases:0.00%
controls:1.87%
—
—
—
—
—
—
—
—
cases:10.00%
controls:5.54%
7
46
79
809
0
16
86
839
—
—
—
—
8
43
72
733
Plastic And Reconstructive Surgery
24 [38004467]
—
2.0e+00
—
—
—
—
1.4e+00
—
—
cases:5.81%
controls:0.82%
—
—
—
—
—
—
—
—
cases:7.50%
controls:1.93%
—
5
7
81
848
—
—
—
—
6
15
74
761
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
cases:0.00%
controls:0.95%
—
—
—
0
8
86
847
—
—
—
0
8
86
835
—
Cystitis, unspecified
N30.9 [45606488]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
80
768
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
3.0e-02
—
—
—
—
—
7.1e-01
cases:6.98%
controls:6.78%
—
—
—
—
—
—
—
—
—
—
cases:15.00%
controls:7.99%
6
58
80
797
—
—
—
—
—
12
62
68
714
Primary gonarthrosis, bilateral
M17.0 [45562648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
0
11
80
765
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:2.84%
—
—
—
—
—
—
6
22
74
754
Acceptance of acknowledgement of paternity of child born outside of marriage before the birth of the child at the maternity clinic. Paternity Act, Section 16.
SPAT1399 [2001700499]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Teeth/gum symptom/complaint
D19 [2002000318]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
86
838
—
Curettage of uterus after delivery or abortion
MBA03 [2001306930]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
86
848
—
—
—
—
—
—
opium derivatives and expectorants
R05FA02 [21603439]
1.3e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.81%
controls:1.64%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
5
14
81
841
0
7
86
848
—
—
—
0
7
86
836
—
Person consulting for explanation of investigation findings
Z71.2 [45552100]
—
-1.0e+50
—
—
—
—
5.7e-01
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
cases:8.75%
controls:5.15%
—
0
8
86
847
—
—
—
—
7
40
73
736
Telehealth
OMOP5556618 [722455]
5.4e-01
7.6e-01
—
—
—
1.6e-01
4.6e-01
cases:23.26%
controls:14.97%
cases:13.95%
controls:7.02%
—
—
—
—
—
—
cases:8.14%
controls:7.00%
cases:27.50%
controls:19.33%
20
128
66
727
12
60
74
795
—
—
—
7
59
79
784
22
150
58
626
Bacteria [Presence] in Urine
87829-8 [36304419]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:2.96%
—
—
—
—
—
—
7
23
73
753
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
5
86
850
0
6
86
849
—
—
—
—
—
topiramate; oral
N03AX11 [21604433]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
5
86
850
—
—
—
—
—
0
7
80
769
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
86
847
—
—
—
—
—
—
Allergic rhinitis due to pollen
J30.10 [2000502594]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
0
11
80
765
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
1.9e+00
—
—
—
—
—
1.5e+00
cases:6.98%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.42%
6
9
80
846
—
—
—
—
—
5
11
75
765
desloratadine; oral
R06AX27 [21603526]
3.7e-01
—
—
—
—
—
5.4e-01
cases:5.81%
controls:4.09%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:5.28%
5
35
81
820
—
—
—
—
—
7
41
73
735
Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
Thyroglobulin Ab [Units/volume] in Serum or Plasma
8098-6 [3025547]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
Emergency Room Visit
ER [9203]
6.4e-01
5.6e-01
1.8e+00
—
—
8.0e-01
4.4e-01
cases:40.70%
controls:26.67%
cases:15.12%
controls:9.24%
cases:5.81%
controls:1.05%
—
—
—
—
cases:19.77%
controls:9.96%
cases:40.00%
controls:30.03%
35
228
51
627
13
79
73
776
5
9
81
846
—
—
17
84
69
759
32
233
48
543
magnesium hydroxide; oral
A02AA04 [21600052]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
chlorhexidine, combinations
D08AC52 [21602208]
1.6e+00
—
—
—
—
—
—
cases:5.81%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
—
—
5
10
81
845
—
—
—
—
—
—
budesonide; inhalant
R03BA02 [21603285]
1.2e+00
1.5e+00
—
—
—
1.3e+00
8.8e-01
cases:10.47%
controls:3.51%
cases:9.30%
controls:2.22%
—
—
—
—
—
—
cases:8.14%
controls:2.25%
cases:10.00%
controls:4.38%
9
30
77
825
8
19
78
836
—
—
—
7
19
79
824
8
34
72
742
Retained molar with obstruction in the upper jaw
K01.16 [2000502661]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
80
769
insulin aspart; parenteral
A10AB05 [21600719]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
0
5
86
850
—
—
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
—
—
—
—
—
8.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:4.38%
—
—
—
—
—
—
8
34
72
742
Other primary gonarthrosis
M17.1 [45596493]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
86
846
—
—
—
—
—
—
cefadroxil; oral
J01DB05 [21602874]
1.2e+00
—
—
—
—
—
-1.0e+50
cases:8.14%
controls:2.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
7
22
79
833
—
—
—
—
—
0
7
80
769
Atrial fibrillation/flutter
K78 [2002000605]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:3.22%
—
—
—
—
—
—
8
25
72
751
General anesthesia, balanced
WX408 [2001310808]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
—
—
—
—
—
1.4e+00
2.9e-01
—
—
—
—
—
—
—
—
—
—
cases:5.81%
controls:1.54%
cases:8.75%
controls:6.70%
—
—
—
—
—
5
13
81
830
7
52
73
724
hypromellose
S01KA02 [21605115]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.29%
—
—
—
—
—
—
5
10
75
766
sildenafil; oral
G04BE03 [21602648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
80
768
Ultrasound examination of uterus and uterine appendages
SPAT1181 [2001700282]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
8.8e-01
1.1e+00
—
—
—
8.2e-01
1.0e+00
cases:13.95%
controls:6.32%
cases:9.30%
controls:3.27%
—
—
—
—
—
—
cases:6.98%
controls:3.20%
cases:17.50%
controls:6.96%
12
54
74
801
8
28
78
827
—
—
—
6
27
80
816
14
54
66
722
Respiratory symptom/complaint other
R29 [2002000898]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
Person encountering health services in unspecified circumstances
Z76.9 [45609967]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:1.55%
0
6
86
849
—
—
—
—
0
7
86
836
0
12
80
764
Periodontitis pronounced
K05.31 [2000502729]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
—
-1.0e+50
—
—
—
—
7.4e-01
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
cases:7.50%
controls:3.74%
—
0
9
86
846
—
—
—
—
6
29
74
747
Otitis externa, unspecified
H60.9 [45605727]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.03%
—
—
—
—
—
—
5
8
75
768
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
6.8e-01
—
—
—
—
—
1.1e+00
cases:5.81%
controls:3.04%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:2.96%
5
26
81
829
—
—
—
—
—
7
23
73
753
Spondylolisthesis
M43.1 [45606219]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
80
770
lamotrigine; oral
N03AX09 [21604431]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
86
838
—
bisoprolol and thiazides
C07BB07 [21601714]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.77%
—
—
—
—
—
0
5
86
838
0
6
80
770
citalopram; oral, parenteral
N06AB04 [21604712]
6.4e-01
1.5e+00
—
—
—
—
—
cases:5.81%
controls:3.16%
cases:5.81%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
5
27
81
828
5
12
81
843
—
—
—
—
—
Spontaneous vertex delivery
O80.0 [45577661]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
0
13
86
842
—
—
—
0
12
86
831
—
Vaccination
SPAT1325 [2001700426]
6.0e-01
-1.0e+50
—
—
—
—
—
cases:5.81%
controls:3.27%
cases:0.00%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
5
28
81
827
0
12
86
843
—
—
—
—
—
metronidazole; oral, rectal
P01AB01 [21604857]
1.0e+00
—
—
—
—
1.3e+00
9.1e-01
cases:11.63%
controls:4.56%
—
—
—
—
—
—
—
—
cases:5.81%
controls:1.66%
cases:13.75%
controls:6.06%
10
39
76
816
—
—
—
—
5
14
81
829
11
47
69
729
Cathetrisation of vein
TPH04 [2001309597]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:2.84%
—
—
—
—
—
—
6
22
74
754
Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
11054-4 [3002109]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
0
7
86
836
—
promethazine, combinations
R06AD52 [21603489]
1.3e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.81%
controls:1.64%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
5
14
81
841
0
7
86
848
—
—
—
0
6
86
837
—
fluocortolone
C05AA08 [21601612]
2.0e+00
—
—
—
—
—
—
cases:5.81%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
5
7
81
848
—
—
—
—
—
—
Extraction of tooth
EBA00 [2001301923]
—
—
—
—
—
—
1.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:6.57%
—
—
—
—
—
—
6
51
74
725
Teeth/gum disease
D82 [2002000380]
7.7e-01
—
—
—
—
—
1.7e-01
cases:10.47%
controls:5.15%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:7.47%
9
44
77
811
—
—
—
—
—
7
58
73
718
Functional capacity evaluation
443351003 [40481051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
86
844
—
—
—
—
—
—
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
80
769
long-acting sulfonamides - combinations
J01ED20 [21602959]
1.3e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.81%
controls:1.64%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
5
14
81
841
0
7
86
848
—
—
—
0
6
86
837
—
azelastine; nasal
R01AC03 [21605035]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:3.87%
—
—
—
—
—
—
6
30
74
746
Warts
S03 [2002000968]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
naproxcinod
M01AE18 [40254094]
2.3e-01
5.6e-01
—
—
—
4.1e-01
2.7e-01
cases:15.12%
controls:12.40%
cases:6.98%
controls:4.09%
—
—
—
—
—
—
cases:6.98%
controls:4.74%
cases:12.50%
controls:9.79%
13
106
73
749
6
35
80
820
—
—
—
6
40
80
803
10
76
70
700
roxithromycin; oral
J01FA06 [21602974]
9.8e-01
—
—
—
—
—
6.1e-01
cases:10.47%
controls:4.21%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:3.48%
9
36
77
819
—
—
—
—
—
5
27
75
749
desogestrel
G03AC09 [21602505]
6.0e-01
—
—
—
—
—
—
cases:5.81%
controls:3.27%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
81
827
—
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
4.8e-01
8.9e-01
—
—
—
3.5e-01
7.8e-01
cases:9.30%
controls:5.96%
cases:8.14%
controls:3.51%
—
—
—
—
—
—
cases:5.81%
controls:4.15%
cases:20.00%
controls:10.31%
8
51
78
804
7
30
79
825
—
—
—
5
35
81
808
16
80
64
696
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
4.6e-01
—
—
—
—
—
7.1e-01
cases:5.81%
controls:3.74%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:5.15%
5
32
81
823
—
—
—
—
—
8
40
72
736
oxcarbazepine; oral
N03AF02 [21604418]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
1.9e+00
—
—
—
—
—
—
cases:5.81%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
5
8
81
847
—
—
—
—
—
—
Irradiated enamel
K03.80 [2000502698]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Assistance to normal delivery
MAX99 [2001306918]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
Emergency Medicine
93 [38004510]
4.1e-02
—
-1.0e+50
—
-1.0e+50
3.3e-01
3.1e-01
cases:8.14%
controls:7.84%
—
—
cases:0.00%
controls:0.82%
—
—
cases:0.00%
controls:0.82%
cases:6.98%
controls:5.10%
cases:16.25%
controls:12.50%
7
67
79
788
—
0
7
86
848
—
0
7
86
848
6
43
80
800
13
97
67
679
clidinium and psycholeptics
A03CA02 [21600204]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
80
770
Recurrent depressive disorder, unspecified
F33.9 [45581458]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
80
770
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:2.84%
—
—
—
—
—
—
6
22
74
754
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
86
848
—
—
—
—
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1.1e+00
—
—
—
—
1.3e+00
3.4e-01
cases:10.47%
controls:3.86%
—
—
—
—
—
—
—
—
cases:5.81%
controls:1.66%
cases:6.25%
controls:4.51%
9
33
77
822
—
—
—
—
5
14
81
829
5
35
75
741
Laboratory Visit
OMOP4822461 [32036]
1.3e-01
2.6e-01
5.3e-01
—
6.3e-01
1.7e-01
1.4e-01
cases:29.07%
controls:26.43%
cases:29.07%
controls:23.98%
cases:12.79%
controls:7.95%
—
—
cases:12.79%
controls:7.25%
cases:27.91%
controls:24.67%
cases:42.50%
controls:39.05%
25
226
61
629
25
205
61
650
11
68
75
787
—
11
62
75
793
24
208
62
635
34
303
46
473
MCH [Entitic mass]
28539-5 [3035941]
1.8e-01
3.2e-01
5.6e-01
—
6.2e-01
5.1e-01
1.4e-01
cases:26.74%
controls:23.39%
cases:24.42%
controls:18.95%
cases:8.14%
controls:4.80%
—
—
cases:6.98%
controls:3.86%
cases:26.74%
controls:18.03%
cases:36.25%
controls:33.12%
23
200
63
655
21
162
65
693
7
41
79
814
—
6
33
80
822
23
152
63
691
29
257
51
519
codeine and paracetamol
N02AJ06 [1123647]
6.0e-01
6.0e-01
-1.0e+50
—
—
1.1e+00
6.3e-01
cases:13.95%
controls:8.19%
cases:5.81%
controls:3.27%
cases:0.00%
controls:0.70%
—
—
—
—
cases:8.14%
controls:2.73%
cases:16.25%
controls:9.41%
12
70
74
785
5
28
81
827
0
6
86
849
—
—
7
23
79
820
13
73
67
703
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
-1.0e+50
-1.0e+50
—
—
—
—
8.5e-01
cases:0.00%
controls:0.94%
cases:0.00%
controls:1.17%
—
—
—
—
—
—
—
—
cases:11.25%
controls:5.15%
0
8
86
847
0
10
86
845
—
—
—
—
9
40
71
736
Laceration/cut
S18 [2002000983]
6.4e-01
—
—
—
—
2.3e+00
1.1e+00
cases:5.81%
controls:3.16%
—
—
—
—
—
—
—
—
cases:5.81%
controls:0.59%
cases:13.75%
controls:5.15%
5
27
81
828
—
—
—
—
5
5
81
838
11
40
69
736
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
6.1e-01
1.0e+00
—
—
—
1.1e+00
6.6e-01
cases:16.28%
controls:9.59%
cases:10.47%
controls:4.09%
—
—
—
—
—
—
cases:11.63%
controls:4.27%
cases:23.75%
controls:13.92%
14
82
72
773
9
35
77
820
—
—
—
10
36
76
807
19
108
61
668
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.4e-01
8.6e-01
—
—
—
1.0e+00
7.1e-01
cases:17.44%
controls:10.99%
cases:11.63%
controls:5.26%
—
—
—
—
—
—
cases:13.95%
controls:5.58%
cases:23.75%
controls:13.27%
15
94
71
761
10
45
76
810
—
—
—
12
47
74
796
19
103
61
673
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
86
846
—
—
—
—
—
—
oxazepam; oral
N05BA04 [21604569]
1.0e+00
—
—
—
—
—
5.7e-01
cases:9.30%
controls:3.63%
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:4.38%
8
31
78
824
—
—
—
—
—
6
34
74
742
Supervision of normal pregnancy
Z34 [45566419]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:1.30%
cases:0.00%
controls:2.32%
—
0
5
86
850
—
—
—
0
11
86
832
0
18
80
758
Placement of prefabricated palatal or lingual arch
SJD40 [2001310441]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
diltiazem; oral
C08DB01 [21601771]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
EKG study
11524-6 [3013512]
—
—
—
—
—
9.8e-01
7.7e-01
—
—
—
—
—
—
—
—
—
—
cases:5.81%
controls:2.25%
cases:7.50%
controls:3.61%
—
—
—
—
—
5
19
81
824
6
28
74
748
hydrocortisone
D07XA01 [21602180]
1.6e+00
—
—
—
—
—
—
cases:5.81%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
—
—
5
10
81
845
—
—
—
—
—
—
insulin (human); parenteral
A10AB01 [21600715]
—
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:1.68%
—
—
0
5
86
850
—
—
—
0
13
80
763
Elevated blood pressure
K85 [2002000612]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
80
769
Anaemia, unspecified
D64.9 [45600610]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
6
86
849
—
—
—
—
—
0
7
80
769
Use of symptom diary
SPAT1359 [2001700460]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
80
769
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.8e-01
3.2e-01
5.6e-01
—
6.2e-01
5.1e-01
1.4e-01
cases:26.74%
controls:23.39%
cases:24.42%
controls:18.95%
cases:8.14%
controls:4.80%
—
—
cases:6.98%
controls:3.86%
cases:26.74%
controls:18.03%
cases:36.25%
controls:33.12%
23
200
63
655
21
162
65
693
7
41
79
814
—
6
33
80
822
23
152
63
691
29
257
51
519
fusidic acid; ointment
D06AX01 [21602062]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.25%
controls:3.87%
—
—
—
—
—
—
9
30
71
746
Insertion of (intrauterine) contraceptive device
Z30.1 [45537626]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
10
86
833
—
Other and unspecified ovarian cysts
N83.2 [45539066]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
80
769
Knee symptom/complaint
L15 [2002000639]
—
—
—
—
—
—
9.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.58%
—
—
—
—
—
—
5
20
75
756
Essential (primary) hypertension
I10 [45591453]
8.8e-01
1.1e+00
—
—
—
1.3e+00
8.0e-01
cases:13.95%
controls:6.32%
cases:11.63%
controls:4.09%
—
—
—
—
—
—
cases:11.63%
controls:3.56%
cases:18.75%
controls:9.41%
12
54
74
801
10
35
76
820
—
—
—
10
30
76
813
15
73
65
703
Tooth X-ray additional picture
EB1CA [2001301909]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
5
86
850
0
6
86
849
—
—
—
—
—
pH of Specimen
17433-4 [3019225]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
86
848
—
—
—
—
—
—
Contraception intrauterine
W12 [2002001212]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
0
7
86
836
—
hydrocortisone
A07EA02 [21600654]
1.0e+00
1.3e+00
—
—
—
1.1e+00
8.0e-01
cases:17.44%
controls:7.02%
cases:5.81%
controls:1.64%
—
—
—
—
—
—
cases:5.81%
controls:2.02%
cases:13.75%
controls:6.70%
15
60
71
795
5
14
81
841
—
—
—
5
17
81
826
11
52
69
724
perphenazine; oral, parenteral, rectal
N05AB03 [21604502]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Hyperglycaemia, unspecified
R73.9 [45602038]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
80
770
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
86
837
—
—
—
—
—
—
Personal history of diseases of the digestive system
Z87.1 [45542474]
—
—
—
—
—
—
2.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:4.90%
—
—
—
—
—
—
5
38
75
738
Trisomy 21 risk [Likelihood] in Fetus
43995-0 [3043238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
86
843
—
—
—
—
—
—
Cough
R05 [2002000886]
1.0e+00
—
—
—
—
—
—
cases:5.81%
controls:2.22%
—
—
—
—
—
—
—
—
—
—
—
—
5
19
81
836
—
—
—
—
—
—
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
4.1e-01
4.7e-01
—
—
—
5.6e-01
5.0e-01
cases:22.09%
controls:15.79%
cases:11.63%
controls:7.60%
—
—
—
—
—
—
cases:11.63%
controls:7.00%
cases:33.75%
controls:23.58%
19
135
67
720
10
65
76
790
—
—
—
10
59
76
784
27
183
53
593
Basophils [#/volume] in Blood
26444-0 [3006315]
7.5e-01
1.0e+00
—
—
—
1.1e+00
1.0e+00
cases:13.95%
controls:7.13%
cases:9.30%
controls:3.51%
—
—
—
—
—
—
cases:9.30%
controls:3.32%
cases:18.75%
controls:7.60%
12
61
74
794
8
30
78
825
—
—
—
8
28
78
815
15
59
65
717
cough suppressants and expectorants
R05FB02 [21603442]
1.3e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.81%
controls:1.64%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
5
14
81
841
0
7
86
848
—
—
—
0
6
86
837
—
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
2.0e+00
—
—
—
—
—
—
cases:5.81%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
5
7
81
848
—
—
—
—
—
—
Dysuria/painful urination
U01 [2002001137]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
Open wound of finger(s) without damage to nail
S61.0 [45578756]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
80
768
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.0e+00
—
-1.0e+50
—
—
1.2e+00
9.8e-01
cases:10.47%
controls:3.98%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
cases:6.98%
controls:2.14%
cases:15.00%
controls:6.19%
9
34
77
821
—
0
5
86
850
—
—
6
18
80
825
12
48
68
728
Missed abortion
O02.1 [45567878]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
0
7
86
848
—
—
—
—
—
0
12
80
764
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:2.73%
—
—
—
—
—
—
0
5
86
850
0
23
86
820
—
methylphenidate; oral
N06BA04 [21604757]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:1.03%
—
—
—
—
—
0
7
86
836
0
8
80
768
Periodontitis complex
K05.30 [2000502728]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
5
86
850
—
—
—
—
—
0
7
80
769
etoricoxib; oral
M01AH05 [21603996]
6.8e-02
—
—
—
—
9.5e-01
-7.3e-01
cases:6.98%
controls:6.55%
—
—
—
—
—
—
—
—
cases:8.14%
controls:3.32%
cases:6.25%
controls:12.11%
6
56
80
799
—
—
—
—
7
28
79
815
5
94
75
682
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
0
9
86
846
—
—
—
—
—
formoterol and budesonide
R03AK07 [21603281]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.40%
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.80%
0
12
86
843
0
9
86
846
—
—
—
—
0
14
80
762
12 lead EKG panel
34534-8 [3044889]
2.7e-01
—
-1.0e+50
—
—
1.1e+00
9.4e-01
cases:10.47%
controls:8.19%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
cases:8.14%
controls:2.97%
cases:21.25%
controls:9.54%
9
70
77
785
—
0
5
86
850
—
—
7
25
79
818
17
74
63
702
Derangement of meniscus due to old tear or injury
M23.2 [45591779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
80
770
Acute conjunctivitis, unspecified
H10.3 [45566958]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
80
768
diclofenac; ointment
M02AA15 [21604051]
1.2e+00
—
—
—
—
—
—
cases:5.81%
controls:1.87%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
81
839
—
—
—
—
—
—
Arthritis, unspecified
M13.9 [45567463]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
80
769
candesartan; oral
C09CA06 [21601829]
—
1.4e+00
—
—
—
1.1e+00
9.8e-01
—
—
cases:6.98%
controls:1.87%
—
—
—
—
—
—
cases:6.98%
controls:2.37%
cases:8.75%
controls:3.48%
—
6
16
80
839
—
—
—
6
20
80
823
7
27
73
749
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
1.3e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.81%
controls:1.64%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
5
14
81
841
0
7
86
848
—
—
—
0
7
86
836
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.6e-01
9.1e-01
—
—
—
8.9e-01
7.6e-01
cases:17.44%
controls:8.19%
cases:9.30%
controls:3.98%
—
—
—
—
—
—
cases:9.30%
controls:4.03%
cases:17.50%
controls:9.02%
15
70
71
785
8
34
78
821
—
—
—
8
34
78
809
14
70
66
706
warfarin; oral, parenteral
B01AA03 [21600965]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:2.45%
—
—
—
—
—
—
6
19
74
757
Nail symptom/complaint
S22 [2002000987]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Otolaryngology
4 [38004449]
3.4e-01
5.3e-01
—
—
—
1.0e+00
5.1e-01
cases:11.63%
controls:8.54%
cases:5.81%
controls:3.51%
—
—
—
—
—
—
cases:8.14%
controls:3.08%
cases:17.50%
controls:11.34%
10
73
76
782
5
30
81
825
—
—
—
7
26
79
817
14
88
66
688
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.8e-01
3.2e-01
5.6e-01
—
6.2e-01
5.1e-01
1.4e-01
cases:26.74%
controls:23.39%
cases:24.42%
controls:18.95%
cases:8.14%
controls:4.80%
—
—
cases:6.98%
controls:3.86%
cases:26.74%
controls:18.03%
cases:36.25%
controls:33.12%
23
200
63
655
21
162
65
693
7
41
79
814
—
6
33
80
822
23
152
63
691
29
257
51
519
Thorax X-ray examination
GD1AA [2001303617]
9.5e-01
—
—
—
—
—
8.0e-01
cases:6.98%
controls:2.81%
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:4.77%
6
24
80
831
—
—
—
—
—
8
37
72
739
chloramphenicol
D10AF03 [21602307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.80%
—
—
—
—
—
—
0
14
80
762
General Practice
1 [38004446]
5.9e-01
1.2e+00
—
—
—
1.0e+00
3.3e-01
cases:11.63%
controls:6.78%
cases:6.98%
controls:2.11%
—
—
—
—
—
—
cases:8.14%
controls:3.08%
cases:15.00%
controls:11.21%
10
58
76
797
6
18
80
837
—
—
—
7
26
79
817
12
87
68
689
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.25%
controls:3.48%
—
—
—
—
—
—
9
27
71
749
clindamycin; oral, parenteral
J01FF01 [21602985]
7.2e-01
—
—
—
—
2.0e+00
9.5e-01
cases:6.98%
controls:3.51%
—
—
—
—
—
—
—
—
cases:5.81%
controls:0.83%
cases:10.00%
controls:4.12%
6
30
80
825
—
—
—
—
5
7
81
836
8
32
72
744
Supervision of normal first pregnancy
Z34.0 [45595500]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
Caries of dentine
K02.1 [45548134]
1.1e-01
3.7e-01
—
—
—
2.4e-01
3.2e-01
cases:12.79%
controls:11.58%
cases:5.81%
controls:4.09%
—
—
—
—
—
—
cases:6.98%
controls:5.58%
cases:21.25%
controls:16.37%
11
99
75
756
5
35
81
820
—
—
—
6
47
80
796
17
127
63
649
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
0
7
86
836
—
Migraine with aura [classical migraine]
G43.1 [45562086]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.40%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
cases:0.00%
controls:1.30%
—
—
0
12
86
843
0
8
86
847
—
—
—
0
11
86
832
—
itraconazole; oral, parenteral
J02AC02 [21603081]
1.5e+00
—
—
—
—
—
—
cases:6.98%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
—
—
6
14
80
841
—
—
—
—
—
—
Contusion of other parts of wrist and hand
S60.2 [45602941]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
7
86
848
—
—
—
—
—
0
7
80
769
Vacuum extractor delivery
O81.4 [45582577]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
hydrocortisone
S01CB03 [21603666]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
Hypertrophy of tonsils
J35.1 [45601127]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
pseudoephedrine, combinations; oral
R01BA52 [21603213]
5.6e-01
—
—
—
—
—
6.7e-01
cases:15.12%
controls:9.24%
—
—
—
—
—
—
—
—
—
—
cases:18.75%
controls:10.57%
13
79
73
776
—
—
—
—
—
15
82
65
694
Normetanephrine [Moles/volume] in Serum or Plasma
25489-6 [3026179]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Senile nuclear cataract
H25.1 [45581628]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
0
5
86
850
—
—
—
0
7
86
836
—
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
6.8e-01
—
—
—
—
—
—
cases:5.81%
controls:3.04%
—
—
—
—
—
—
—
—
—
—
—
—
5
26
81
829
—
—
—
—
—
—
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
—
9.5e-01
—
—
—
—
1.1e+00
—
—
cases:5.81%
controls:2.34%
—
—
—
—
—
—
—
—
cases:13.75%
controls:5.03%
—
5
20
81
835
—
—
—
—
11
39
69
737
Hip symptom/complaint
L13 [2002000637]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Hepatitis B virus core and surface Ab and surface Ag panel - Serum
77190-7 [46237023]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Home Visit
OMOP4822459 [581476]
4.6e-01
—
—
—
—
—
5.2e-01
cases:5.81%
controls:3.74%
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:5.41%
5
32
81
823
—
—
—
—
—
7
42
73
734
Pediatric Medicine
37 [38004477]
2.5e-01
9.5e-01
—
—
—
—
—
cases:8.14%
controls:6.43%
cases:5.81%
controls:2.34%
—
—
—
—
—
—
—
—
—
—
7
55
79
800
5
20
81
835
—
—
—
—
—
Health check-up performed during first study year in students of upper secondary schools, vocational schools etc.
SPAT1363 [2001700464]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
86
838
—
ethylmorphine; oral
R05DA01 [21603397]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.32%
—
—
—
—
—
—
5
18
75
758
finasteride; oral
G04CB01 [21602675]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.77%
0
5
86
850
0
5
86
850
—
—
—
0
5
86
838
0
6
80
770
Occupational health examination
Z10.0 [45581006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
86
848
—
—
—
—
—
—
Unspecified fall
W19 [45756257]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
7
86
848
—
—
—
—
—
0
5
80
771
Morphology ultrasound screening, weeks 18+0 to 21+6 of gestation
MA5AE [2001306841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Diabetes insulin dependent
T89 [2002001130]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
0
7
86
848
0
7
86
848
—
—
—
0
6
86
837
—
Benzodiazepines [Presence] in Urine
3390-2 [3000764]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
Acute suppurative otitis media
H66.0 [45572040]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
86
843
—
—
—
—
—
—
Respiratory and circulatory monitoring
WX700 [2001310817]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.64%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
0
14
86
841
0
5
86
850
—
—
—
—
—
Outcome of delivery
Z37 [45581024]
-6.3e-03
-1.0e+50
—
—
—
-1.0e+50
-1.2e-01
cases:8.14%
controls:8.19%
cases:0.00%
controls:2.81%
—
—
—
—
—
—
cases:0.00%
controls:1.90%
cases:7.50%
controls:8.38%
7
70
79
785
0
24
86
831
—
—
—
0
16
86
827
6
65
74
711
Other oral or dental procedure
SXC05 [2001310586]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
86
838
—
Prolactin [Units/volume] in Serum or Plasma
15081-3 [3021387]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.42%
—
—
—
—
—
—
5
11
75
765
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
Hypothyroidism, unspecified
E03.9 [45537945]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
Structured assessment of psychoactive substance / tobacco use
SPAT1273 [2001700374]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
8
80
768
hydrocortisone
D07AA02 [21602102]
9.6e-01
1.3e+00
—
—
—
1.1e+00
8.0e-01
cases:16.28%
controls:6.90%
cases:5.81%
controls:1.64%
—
—
—
—
—
—
cases:5.81%
controls:2.02%
cases:13.75%
controls:6.70%
14
59
72
796
5
14
81
841
—
—
—
5
17
81
826
11
52
69
724
Sprain and strain of cervical spine
S13.4 [45573197]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
6
80
770
Systematic individual therapy, cognitive-behavioural
IDY03 [2001304164]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
80
769
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
86
837
—
—
—
—
—
—
Malignant neoplasm of breast
C50 [45571518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
celecoxib; oral
M01AH01 [21603992]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
0
7
86
836
—
Severe psychotic and other severe mental disorders
112 [2001600112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
86
847
—
—
—
—
—
—
carbamazepine; oral, rectal
N03AF01 [21604417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
Health maint/preventive medicine
A98 [2002000231]
1.8e-01
3.3e-01
—
—
—
-1.4e-01
2.1e-01
cases:30.23%
controls:26.67%
cases:24.42%
controls:18.83%
—
—
—
—
—
—
cases:18.60%
controls:20.76%
cases:45.00%
controls:39.82%
26
228
60
627
21
161
65
694
—
—
—
16
175
70
668
36
309
44
467
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
Extensive health check-up of children and adolescents
SPAT1316 [2001700417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
86
845
—
—
—
—
—
—
Gastroenteritis presumed infection
D73 [2002000371]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Maternal and Fetal Medicine
OMOP4821963 [45756780]
1.4e+00
-1.0e+50
—
—
—
—
—
cases:5.81%
controls:1.52%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
5
13
81
842
0
5
86
850
—
—
—
—
—
candesartan and diuretics
C09DA06 [21601838]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
digoxin; oral, parenteral
C01AA05 [21600234]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
hydrocortisone aceponate
D07AC16 [21602135]
9.6e-01
1.3e+00
—
—
—
1.1e+00
8.0e-01
cases:16.28%
controls:6.90%
cases:5.81%
controls:1.64%
—
—
—
—
—
—
cases:5.81%
controls:2.02%
cases:13.75%
controls:6.70%
14
59
72
796
5
14
81
841
—
—
—
5
17
81
826
11
52
69
724
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
0
7
86
848
—
—
Issue of medical certificate
Z02.7 [45537613]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
0
6
86
849
—
—
—
—
—
0
6
80
770
hydrocortisone and antiseptics
D07BA04 [21602146]
1.6e+00
—
—
—
—
—
—
cases:5.81%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
—
—
5
10
81
845
—
—
—
—
—
—
chloramphenicol; ointment
D06AX02 [21602063]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.80%
—
—
—
—
—
—
0
14
80
762
Monitoring of normal pregnancy
SPAT1196 [2001700297]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
0
5
86
850
0
5
86
850
—
—
—
—
—
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
0
5
86
850
—
—
—
—
0
6
80
770
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
5
86
850
0
6
86
849
—
—
—
—
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
5.3e-01
4.1e-01
—
—
—
5.5e-01
4.4e-01
cases:25.58%
controls:16.84%
cases:16.28%
controls:11.46%
—
—
—
—
—
—
cases:18.60%
controls:11.63%
cases:32.50%
controls:23.71%
22
144
64
711
14
98
72
757
—
—
—
16
98
70
745
26
184
54
592
platelet aggregation inhibitors excl. heparin - combinations
B01AC30 [21601005]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
0
5
86
850
0
5
86
850
—
—
—
—
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.0e+00
1.3e+00
—
—
—
1.2e+00
7.8e-01
cases:13.95%
controls:5.50%
cases:8.14%
controls:2.34%
—
—
—
—
—
—
cases:9.30%
controls:2.97%
cases:13.75%
controls:6.83%
12
47
74
808
7
20
79
835
—
—
—
8
25
78
818
11
53
69
723
Acute pericoronitis
K05.22 [2000502725]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
0
12
80
764
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
5
86
838
—
glibenclamide; oral
A10BB01 [21600750]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
Contact with and exposure to other communicable diseases
Z20.8 [45542410]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
0
6
86
849
—
—
—
—
—
0
7
80
769
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
1.7e+00
—
—
—
—
—
1.4e+00
cases:6.98%
controls:1.29%
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:1.93%
6
11
80
844
—
—
—
—
—
6
15
74
761
Erysipelas
A46 [45561706]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.93%
—
—
—
—
—
—
5
15
75
761
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
5
86
850
—
0
7
86
848
—
—
mometasone
D07AC13 [21602132]
8.9e-01
—
—
—
—
—
—
cases:8.14%
controls:3.51%
—
—
—
—
—
—
—
—
—
—
—
—
7
30
79
825
—
—
—
—
—
—
Single live birth
Z37.0 [45571346]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.29%
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.55%
0
11
86
844
0
8
86
847
—
—
—
—
0
12
80
764
Radiological examination, not elsewhere classified
Z01.6 [45605096]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
No disease
A97 [2002000230]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.58%
—
—
—
—
—
—
0
20
80
756
finasteride; oral
D11AX10 [21602350]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.58%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.77%
0
5
86
850
0
5
86
850
—
—
—
0
5
86
838
0
6
80
770
prednisone; oral
H02AB07 [21602735]
1.6e+00
—
—
—
—
—
—
cases:6.98%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
—
6
13
80
842
—
—
—
—
—
—
Other stressful life events affecting family and household
Z63.7 [45537662]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
5
80
771
Demanding periodontal treatment
SDA04 [2001310329]
1.1e+00
—
—
—
—
—
—
cases:6.98%
controls:2.34%
—
—
—
—
—
—
—
—
—
—
—
—
6
20
80
835
—
—
—
—
—
—
Naevus/mole
S82 [2002001046]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
86
842
—
—
—
—
—
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
5.5e-01
4.2e-01
-1.0e+50
—
—
7.1e-01
5.2e-01
cases:12.79%
controls:7.84%
cases:6.98%
controls:4.68%
cases:0.00%
controls:1.17%
—
—
—
—
cases:8.14%
controls:4.15%
cases:18.75%
controls:12.11%
11
67
75
788
6
40
80
815
0
10
86
845
—
—
7
35
79
808
15
94
65
682
Two-surface restoration
SFA20 [2001310359]
-1.7e-01
4.9e-01
—
—
—
4.4e-01
5.1e-01
cases:9.30%
controls:10.88%
cases:5.81%
controls:3.63%
—
—
—
—
—
—
cases:6.98%
controls:4.63%
cases:21.25%
controls:13.92%
8
93
78
762
5
31
81
824
—
—
—
6
39
80
804
17
108
63
668
Post-traumatic stress disorder
F43.1 [45595909]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
86
850
—
—
—
—
—
—
levocabastine
S01GX02 [21605086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
86
848
—
—
—
—
—
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
86
846
—
—
—
—
—
—
Endomysium IgA Ab [Titer] in Serum
10863-9 [3020961]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
0
9
86
846
—
—
—
—
—
0
8
80
768
Disease/condition unspecnature/site
A99 [2002000232]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
86
846
—
—
—
—
—
—
Inpatient Visit
IP [9201]
3.0e-01
—
—
1.0e+50
—
1.2e+00
5.0e-01
cases:6.98%
controls:5.26%
—
—
—
—
cases:9.30%
controls:0.00%
—
—
cases:6.98%
controls:2.14%
cases:10.00%
controls:6.31%
6
45
80
810
—
—
8
0
78
855
—
6
18
80
825
8
49
72
727
X-ray examination of the lungs in one projection
GD1PA [2001303645]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
Hyperlipidaemia, unspecified
E78.5 [45537986]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
0
7
80
769
Choriogonadotropin [Units/volume] in Urine
25372-4 [3023511]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—
Ear microscopy
UDC00 [2001301558]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
0
7
86
848
—
—
—
—
—
0
6
80
770
Removal of sutures
SPAT1153 [2001700254]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
7
86
848
—
—
—
—
—
bupivacaine
N01BB01 [21604229]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
86
849
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
39
98
5.27
15.42
2.7
1.5
—
—
—
0
0
34
121
3.46
8.04
10.9
4.4
1.04
1.00
mmol/l
0.41
34
115
18
40
5.07
7.93
1.6
1.1
—
—
—
0
0
79
496
2.53
6.09
10.9
5.9
1.21
1.22
mmol/l
0.12
71
430
60
353
2.31
5.09
6.7
5.6
—
—
—
0
0
28
115
2.83
5.06
2.1
1.4
—
—
—
0
0
31
137
2.66
4.87
2.5
2.0
—
—
—
0
0
78
540
2.12
4.14
8.2
5.7
27.08
28.21
%
0.44
72
520
76
526
2.08
3.98
8.3
5.7
2.42
2.78
%
1.21
69
500
76
526
2.08
3.98
8.3
5.7
8.12
8.57
%
0.81
69
499
79
557
2.08
3.91
3.7
3.1
133.15
99.24
ug/l
0.77
72
532
6
5
12.49
3.80
1.3
1.2
—
—
—
0
0
75
526
2.02
3.69
8.4
5.7
0.78
0.65
%
1.07
69
498
76
537
2.01
3.64
8.0
5.6
59.56
56.92
%
1.38
70
517
78
569
1.94
3.27
8.3
5.8
0.58
0.55
e9/l
0.47
66
488
78
571
1.93
3.22
8.4
5.8
0.05
0.04
e9/l
0.93
66
490
79
588
1.89
3.02
8.4
5.8
1.88
1.99
e9/l
0.34
69
522
83
628
1.90
3.01
10.8
9.9
4.66
3.99
e9/l
0.90
73
540
5
5
10.33
3.00
1.4
1.0
—
—
—
0
0
79
589
1.88
3.00
8.4
5.8
0.19
0.19
e9/l
0.02
67
514
19
84
2.48
2.94
4.3
4.3
0.56
0.73
%
—
9
22
28
149
2.12
2.84
1.9
1.6
970.47
1162.07
nmol/l
0.56
23
114
7
14
5.22
2.77
2.6
2.1
—
—
—
0
0
63
452
1.77
2.59
11.8
10.2
1.18
1.17
inr
0.07
56
372
6
11
5.66
2.57
2.5
4.1
5.02
6.70
e9/l
—
6
11
11
37
3.15
2.56
6.3
2.1
—
—
—
0
0
48
322
1.78
2.45
7.7
3.4
7.39
7.40
ph
0.00
36
221
30
176
1.92
2.32
3.5
3.1
272.48
66.19
ng/l
0.50
23
117
102
862
1.88
2.22
5.0
4.2
14.47
14.64
pmol/l
0.26
97
793
11
43
2.70
2.14
1.4
1.5
9.30
7.05
u/l
0.17
11
33
41
272
1.74
2.14
2.6
2.0
3.07
2.71
mg/l
0.56
36
233
13
56
2.47
2.12
1.8
2.6
—
—
—
0
0
48
336
1.68
2.05
3.4
3.0
—
—
—
0
0
41
277
1.70
1.99
7.0
4.2
—
—
—
0
0
13
58
2.38
1.98
1.2
1.3
—
—
—
0
0
17
86
2.13
1.96
5.0
4.7
0.00
0.00
%
—
7
18
36
236
1.73
1.94
1.9
1.8
0.75
1.27
mg/l
0.86
27
179
11
46
2.52
1.91
2.0
1.9
35.09
40.33
nmol/l
0.19
11
46
112
992
1.98
1.87
8.8
5.5
40.14
38.56
mmol/mol
1.09
107
935
43
299
1.66
1.86
4.8
3.2
116.28
54.49
mg/l
0.70
33
182
44
310
1.64
1.80
5.4
3.8
21.96
8.44
mg/mmol
0.85
35
180
13
61
2.26
1.78
1.2
1.4
—
63.11
—
0
7
6
18
3.44
1.77
2.5
3.1
64.33
63.14
%
—
6
18
11
48
2.41
1.76
1.0
1.2
—
—
—
0
0
16
83
2.06
1.73
5.2
4.4
0.17
0.05
%
—
6
19
7
25
2.90
1.67
1.1
1.3
—
—
—
0
0
41
290
1.61
1.64
1.8
1.6
20.02
20.98
nmol/l
0.18
36
251
5
14
3.67
1.63
1.4
1.4
16.78
33.57
ng/l
—
5
14
7
26
2.79
1.60
8.7
2.5
22.23
25.11
mmol/l
—
7
26
6
20
3.09
1.60
9.2
3.4
16.02
11.55
pmol/l
—
6
20
30
197
1.68
1.59
1.4
1.3
19.59
25.94
iu/ml
—
9
55
16
86
1.98
1.59
5.3
4.3
1.17
0.39
%
—
6
23
21
128
1.77
1.44
1.2
1.3
—
—
—
0
0
61
485
1.49
1.41
4.4
3.3
6.31
6.18
ph
0.36
36
277
6
23
2.68
1.38
7.0
4.6
7.41
7.42
ph
—
6
23
5
17
3.02
1.37
1.8
1.1
—
—
—
0
0
73
606
1.47
1.33
4.7
3.7
0.00
0.00
estimate
-0.00
12
127
73
608
1.46
1.30
4.6
3.8
0.00
0.00
estimate
-0.00
11
120
17
101
1.79
1.27
5.7
7.1
7.42
7.42
ph
—
8
62
27
183
1.60
1.27
1.4
1.3
1.19
7.20
u/ml
—
10
65
20
125
1.71
1.27
6.0
5.9
105.30
104.51
mmol/l
0.27
20
125
16
95
1.78
1.20
3.4
2.5
7.36
7.39
ph
—
10
50
55
440
1.44
1.18
2.5
1.9
93.74
94.42
pmol/l
0.04
37
214
8
39
2.12
1.17
4.3
3.6
36.90
36.94
°c
—
8
39
71
596
1.43
1.17
4.6
3.7
0.00
0.00
estimate
-0.00
11
123
21
137
1.64
1.14
2.7
1.9
27.40
29.42
s
1.22
21
132
36
271
1.46
1.05
7.1
4.0
—
—
—
0
0
7
35
2.06
1.01
1.4
1.3
—
—
—
0
0
51
413
1.39
0.99
2.6
1.9
—
—
—
0
0
9
50
1.86
0.99
3.8
2.4
0.68
0.62
%
—
9
50
37
468
0.71
0.98
3.6
3.0
—
—
—
0
0
19
126
1.60
0.98
1.5
1.4
—
—
—
0
0
9
51
1.82
0.97
3.0
4.1
—
—
—
0
0
9
51
1.82
0.97
3.9
2.4
1.38
1.15
%
—
9
51
9
51
1.82
0.97
7.1
6.9
24.03
24.50
mmol/l
—
9
51
36
276
1.42
0.95
4.8
3.6
1.02
1.02
kg/l
0.11
26
170
84
742
1.38
0.94
6.1
4.6
—
2954.00
—
0
19
56
465
1.36
0.92
1.8
1.9
1.57
1.36
mmol/l
0.57
46
390
12
71
1.76
0.92
8.0
3.6
—
—
—
0
0
36
278
1.41
0.91
1.6
1.5
2.29
2.46
g/l
0.13
24
163
61
517
1.34
0.87
19.6
10.8
0.00
0.00
e9/l
0.50
49
420
11
65
1.76
0.85
1.1
1.1
—
—
—
0
0
23
166
1.47
0.83
2.4
1.6
—
—
—
0
0
0
25
0.00
0.80
0.0
1.0
—
0.15
—
0
11
13
83
1.63
0.78
7.0
5.8
1.15
1.20
mmol/l
0.11
13
83
9
53
1.75
0.77
7.6
8.8
94.16
94.67
%
—
9
53
15
100
1.57
0.77
1.7
1.7
—
—
—
0
0
9
55
1.68
0.75
7.6
8.4
1.20
1.36
%
—
9
55
9
55
1.68
0.75
7.4
8.4
0.77
0.64
%
—
9
55
42
344
1.33
0.74
3.7
3.1
—
0.00
—
0
8
54
460
1.30
0.71
4.3
3.5
0.00
0.01
estimate
—
10
105
60
524
1.27
0.64
3.4
2.6
—
—
estimate
—
0
0
13
88
1.53
0.63
1.5
1.4
—
—
—
0
0
13
88
1.53
0.63
6.4
5.9
—
—
—
0
0
38
314
1.30
0.62
1.3
1.3
0.66
1.46
u/ml
—
8
83
12
172
0.67
0.61
1.9
1.7
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
0.48
—
0
10
18
133
1.41
0.59
1.6
1.2
—
—
—
0
0
9
60
1.54
0.56
4.9
2.4
1.01
1.02
ratio
—
9
55
49
425
1.25
0.54
4.5
3.7
12.50
36.35
e6/l
2.19
38
289
6
40
1.52
0.52
3.8
5.3
0.90
0.92
%
—
6
35
9
65
1.41
0.52
1.4
1.2
—
—
—
0
0
7
45
1.59
0.50
3.9
4.9
1.24
1.52
%
—
7
39
43
372
1.23
0.48
3.8
2.9
19.66
21.88
e6/l
0.10
37
281
40
346
1.23
0.44
3.1
3.1
0.00
0.00
estimate
—
8
98
0
18
0.00
0.40
0.0
1.1
—
1.39
—
0
6
41
362
1.19
0.37
2.7
2.1
—
—
—
0
0
36
314
1.20
0.37
5.9
5.9
—
—
—
0
0
91
955
0.84
0.35
30.0
17.1
13.66
13.48
%
0.58
91
949
6
45
1.35
0.34
1.0
1.2
1.44
1.56
g/l
—
6
45
6
46
1.32
0.33
1.0
1.2
0.87
0.85
g/l
—
6
46
36
317
1.19
0.33
3.8
2.8
0.24
0.33
e6/l
0.36
29
230
7
55
1.29
0.30
3.9
2.3
23.36
24.23
mmol/l
—
7
55
5
71
0.69
0.27
1.4
1.5
—
—
—
0
0
5
72
0.68
0.27
1.4
1.4
—
—
—
0
0
5
72
0.68
0.27
1.4
1.4
—
—
—
0
0
5
73
0.67
0.27
1.4
1.4
—
—
—
0
0
36
323
1.16
0.27
4.7
3.7
0.00
0.00
estimate
—
10
115
18
212
0.82
0.26
2.4
1.8
—
—
—
0
0
29
257
1.17
0.25
2.3
1.8
—
—
—
0
0
14
115
1.24
0.24
1.4
1.3
—
—
—
0
0
15
125
1.23
0.23
1.1
1.2
—
—
—
0
0
5
39
1.29
0.23
1.2
1.1
—
—
—
0
0
28
312
0.87
0.22
2.7
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
7.8
—
6.77
—
0
10
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
112
1093
1.19
0.21
27.9
13.5
19.18
24.11
mg/l
1.26
97
881
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
112
1143
0.85
0.19
25.7
11.9
—
—
—
0
0
5
67
0.74
0.17
1.4
1.4
—
—
—
0
0
110
1083
1.11
0.10
7.0
5.1
2.72
2.73
mmol/l
0.03
105
1021
39
373
1.07
0.08
4.5
3.8
42.34
30.71
ng/l
0.38
25
245
38
370
1.04
0.03
1.6
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
2.7
—
1812.78
—
0
9
9
96
0.93
0.00
2.3
3.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
9.5
—
17.21
—
0
8
0
5
0.00
-0.00
0.0
3.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
63.00
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint L12_ACANTHNIGRICANS and mortality.

Females

Parameter HR [95% CI] p-value
L12_ACANTHNIGRICANS 1.857 [1.28, 2.7] 0.001
Birth year 0.999 [0.99, 1.01] 0.827

During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 312 females with L12_ACANTHNIGRICANS died.

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_ACANTHNIGRICANS.

N-year risk Females Males
1 0.187% No data
5 1.092% No data
10 2.893% No data
15 5.937% No data
20 10.56% No data

Relationships between endpoints

↥

Index endpoint: L12_ACANTHNIGRICANS – Acanthosis nigricans

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data